Table 4.

Phases II trials evaluating carboplatin based doublets

Auteur	Treatment	No	Results
Redman et al [28]	PCa	35	ORR = 51%; OS = 9.5 months
Small et al [29]	PCa	29	ORR = 20,7%; TTP = 4 months; OS = 9 months
Vaughn et al [30]	PCa	33	ORR = 50%
Bellmunt et al [32]	GCa	16	ORR = 44%
Nogue-Aliguer et al [33]	GCa	41	ORR = 56.1%; PFS = 7.2 months; OS = 10.1 months
Shannon et al [34]	GCa	17	ORR = 58.8%; PFS = 4.6 months; OS = 10.5 mois
Dogliotti et al [35]	GCa vs. GC (Randomized phase II)	110	Efficacy: CR: 1.8% vs. 14.5%; OS: 9.8 vs. 12.8 months Toxicity: Equivalent.

Abbreviations. PCa: paclitaxel-carboplatin; GCa: gemcitabine-carboplatin; GC: gemcitabine-cisplatin; ORR: objective response rate; OS: overall survival; PFS: progression free survival